The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 03, 2013
Filed:
Nov. 12, 2009
Antonio J. M. Barbosa, Jr., Middlebury, CT (US);
Peter A. Blomgren, North Branford, CT (US);
Kevin S. Currie, North Branford, CT (US);
Seung Lee, Branford, CT (US);
Jeffrey E. Kropf, Branford, CT (US);
Scott A. Mitchell, East Haven, CT (US);
Daniel Ortwine, San Ramon, CA (US);
William M. Rennells, Schenectady, NY (US);
Aaron C. Schmitt, Hamden, CT (US);
Jianjun Xu, Madison, CT (US);
Wendy B. Young, San Mateo, CA (US);
Zhongdong Zhao, Guilford, CT (US);
Pavel E. Zhichkin, Delmar, NY (US);
Antonio J. M. Barbosa, Jr., Middlebury, CT (US);
Peter A. Blomgren, North Branford, CT (US);
Kevin S. Currie, North Branford, CT (US);
Seung Lee, Branford, CT (US);
Jeffrey E. Kropf, Branford, CT (US);
Scott A. Mitchell, East Haven, CT (US);
Daniel Ortwine, San Ramon, CA (US);
William M. Rennells, Schenectady, NY (US);
Aaron C. Schmitt, Hamden, CT (US);
Jianjun Xu, Madison, CT (US);
Wendy B. Young, San Mateo, CA (US);
Zhongdong Zhao, Guilford, CT (US);
Pavel E. Zhichkin, Delmar, NY (US);
Genetech, Inc., South San Francisco, CA (US);
Gilead Connecticut, Inc., Foster City, CA (US);
Abstract
Compounds of Formula I that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.